The Cost-Effectiveness of Real-Time Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Background: This analysis models the cost-effectiveness of real-time continuous glucose monitoring (RT-CGM) using evidence from a randomized controlled trial (RCT) that demonstrated RT-CGM reduced A1C, for up to 9 months after using the technology, among patients with type 2 diabetes not on prandial insulin. RT-CGM was offered short-term and intermittently as a self-care tool to inform patients’ behavior. Method: The analyses projected lifetime clinical and economic outcomes for RT-CGM versus self-monitoring of blood glucose by fingerstick only. The base-case analysis was consistent with the RCT (RT-CGM for 2 weeks on/1 week off over 3 months). A scenario analysis simulated outcomes of an RT-CGM “refresher” after the active intervention of the RCT. Analyses used the IMS CORE Diabetes Model and were conducted from a US third-party payer perspective, including direct costs obtained from published sources and inflated to 2011 US dollars. Costs and health outcomes were discounted at 3% per annum. Results: Life expectancy (LE) and quality-adjusted life expectancy (QALE) from RT-CGM were 0.10 and 0.07, with a cost of $653/patient over a lifetime. Incremental LE and QALE from a “refresher” were 0.14 and 0.10, with a cost of $1312/patient over a lifetime, and incremental cost-effectiveness ratios were $9319 and $13 030 per LY and QALY gained. Conclusions: RT-CGM, as a self-care tool, is a cost-effective disease management option in the US for people with type 2 diabetes not on prandial insulin. Repeated use of RT-CGM may result in additional cost-effectiveness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Fonda and colleagues 59 reported on the cost‐effectiveness of the periodic rtCGM intervention previously reported by Ehrhardt et al. 33 Based on 2011 pricing, they found that intermittent rtCGM was a cost‐effective option, with incremental cost‐effectiveness ratios of $9319 and $13 030 per (life year) LY and (quality‐adjusted life year) QALY gained, substantially lower than typical ‘willingness‐to”
Citations
Cites
The "what" and "why" of goal pursuits: Human needs and the self-determination of behavior
Deci, E. L., & Ryan, R. M. (2000) · Psychological Inquiry · doi:10.1207/s15327965pli1104_01 · Cited by 34,210
Intrinsic and Extrinsic Motivations: Classic Definitions and New Directions
Ryan, R. M., & Deci, E. L. (2000) · Contemporary Educational Psychology · doi:10.1006/ceps.1999.1020 · Cited by 18,666
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Gruberg, L., Weissman, N. J., Waksman, R., Fuchs, S., Deible, R., Pinnow, E. E., Ahmed, L. M., Kent, K. M., Pichard, A. D., Suddath, W. O., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01802-2 · Cited by 696
Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 Diabetes
Koro, C. E., Bowlin, S. J., Bourgeois, N., & Fedder, D. O. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.17 · Cited by 648
Braithwaite, R. S., Meltzer, D. O., King, J. T., Leslie, D., & Roberts, M. S. (2008) · Medical Care · doi:10.1097/mlr.0b013e31815c31a7 · Cited by 579 · cited 1×
“Recent studies suggest that the acceptable threshold in the US setting could actually be much higher—in the range of $109 000-$297 000 per QALY gained.(27) By comparison, a cost-effectiveness analysis using inputs from the Juvenile Diabetes Research–Continuous Glucose Monitoring (CGM) Trials in people with type 1 diab…”
MethodDeiss, D., Bolinder, J., Riveline, J.-P., Battelino, T., Bosi, E., Tubiana-Rufi, N., Kerr, D., & Phillip, M. (2006) · Diabetes Care · doi:10.2337/dc06-1134 · Cited by 539
Palmer, A. J., Roze, S., Valentine, W. J., Minshall, M. E., Foos, V., Lurati, F. M., Lammert, M., & Spinas, G. A. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x1980 · Cited by 526
Effect of Continuous Glucose Monitoring on Hypoglycemia in Type 1 Diabetes
Battelino, T., Phillip, M., Bratina, N., Nimri, R., Oskarsson, P., & Bolinder, J. (2011) · Diabetes Care · doi:10.2337/dc10-1989 · Cited by 490
Improvement in Glycemic Excursions With a Transcutaneous, Real-Time Continuous Glucose Sensor
Garg, S., Zisser, H., Schwartz, S., Bailey, T., Kaplan, R., Ellis, S., & Jovanovic, L. (2006) · Diabetes Care · doi:10.2337/diacare.29.01.06.dc05-1686 · Cited by 433
Polonsky, W. H., Fisher, L., Schikman, C. H., Hinnen, D. A., Parkin, C. G., Jelsovsky, Z., Petersen, B., Schweitzer, M., & Wagner, R. S. (2011) · Diabetes Care · doi:10.2337/dc10-1732 · Cited by 429
The effect of continuous glucose monitoring in well-controlled type 1 diabetes
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0108 · Cited by 399
Cost-effectiveness of Systematic Depression Treatment Among People With Diabetes Mellitus
Simon, G. E., Katon, W. J., Lin, E. H. B., Rutter, C., Manning, W. G., Von Korff, M., Ciechanowski, P., Ludman, E. J., & Young, B. A. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.1.65 · Cited by 311
Vigersky, R. A., Fonda, S. J., Chellappa, M., Walker, M. S., & Ehrhardt, N. M. (2012) · Diabetes Care · doi:10.2337/dc11-1438 · Cited by 301
Self-citationValidation of the CORE Diabetes Model Against Epidemiological and Clinical Studies
Palmera, A. J., Rozea, S., Valentinea, W. J., Minshallb, M. E., Foosa, V., Luratia, F. M., Lammerta, M., & Spinasc, G. A. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x2006 · Cited by 284
Yoo, H. J., An, H. G., Park, S. Y., Ryu, O. H., Kim, H. Y., Seo, J. A., Hong, E. G., Shin, D. H., Kim, Y. H., Kim, S. G., et al. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.06.015 · Cited by 244
O’Connell, M. A., Donath, S., O’Neal, D. N., Colman, P. G., Ambler, G. R., Jones, T. W., Davis, E. A., & Cameron, F. J. (2009) · Diabetologia · doi:10.1007/s00125-009-1365-0 · Cited by 211
Ehrhardt, N. M., Chellappa, M., Walker, M. S., Fonda, S. J., & Vigersky, R. A. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500320 · Cited by 199 · cited 5×
“The testing data were used to guide health care providers’ decision making, rather than to guide patient decision making, which was the focus of the RT-CGM RCT.”
BackgroundMethodInfluentialSelf-citationBailey, T. S., Zisser, H. C., & Garg, S. K. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2007.0205 · Cited by 159
The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes
Huang, E. S., O'Grady, M., Basu, A., Winn, A., John, P., Lee, J., Meltzer, D., Kollman, C., Laffel, L., Tamborlane, W., et al. (2010) · Diabetes Care · doi:10.2337/dc09-2042 · Cited by 117
Yeaw, J., Lee, W. C., Aagren, M., & Christensen, T. (2012) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2012.18.1.21 · Cited by 98
McQueen, R. B., Ellis, S. L., Campbell, J. D., Nair, K. V., & Sullivan, P. W. (2011) · Cost Effectiveness and Resource Allocation · doi:10.1186/1478-7547-9-13 · Cited by 74
Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting
Pelletier, E. M., Smith, P., Boye, K. S., Misurski, D. A., Tunis, S. L., & Minshall, M. E. (2008) · Applied Health Economics and Health Policy · doi:10.1007/bf03256126 · Cited by 61
Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the united states.
Tunis, S. L., & Minshall, M. E. (2008) · PubMed · Cited by 49
Perceived Accuracy in Continuous Glucose Monitoring: Understanding the Impact on Patients
Polonsky, W. H., & Hessler, D. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814559302 · Cited by 47
Minshall, M. E., Oglesby, A. K., Wintle, M. E., Valentine, W. J., Roze, S., & Palmer, A. J. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00211.x · Cited by 42
Tunis, S. L., & Minshall, M. E. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903400071 · Cited by 33
Fonda, S. J., Salkind, S. J., Walker, M. S., Chellappa, M., Ehrhardt, N. M., & Vigersky, R. A. (2012) · Diabetes Care · doi:10.2337/dc12-1225 · Cited by 28
Self-citationTunis, S. L., Willis, W. D., & FOOS, V. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903429765 · Cited by 27
Pollock, R. F., Valentine, W. J., Goodall, G., & Brändle, M. (2010) · Swiss Medical Weekly · doi:10.4414/smw.2010.13103 · Cited by 22
Lee, W. C., Conner, C., & Hammer, M. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.559444 · Cited by 16
Tunis, S. L. (2011) · Applied Health Economics and Health Policy · doi:10.2165/11594270-000000000-00000 · Cited by 14
Research works printed but not linked: 2
- Pollock RF, 2010, Swiss Med Wkly, 140, w13103
- Tunis SL, 2008, Am J Manag Care, 14, 131
Cited by
Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes
Rodbard, D. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0035 · Cited by 458
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Ruedy, K. J., Parkin, C. G., Riddlesworth, T. D., & Graham, C. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817704445 · Cited by 225
Self-citationClinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes
Carlson, A. L., Mullen, D. M., & Bergenstal, R. M. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0024 · Cited by 177
Glycemic variability: how to measure and its clinical implication for type 2 diabetes
Umpierrez, G. E., & P. Kovatchev, B. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.09.010 · Cited by 148
Metadata
- Authors
- Fonda, S. J., Graham, C., Munakata, J., Powers, J. M., Price, D., & Vigersky, R. A.
- Affiliations
- Walter Reed National Military Medical Center (US)
- Dexcom (United States) (US)
- IQVIA (United States) (US)
- University of Colorado Denver (US)
- Corresponding author
- Fonda, Stephanie J.
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2016-02-03
- Volume
- 10
- Issue
- 4
- Pages
- 898-904
- ISSN
- 1932-2968 (ISSN-L)
- PMC
- PMC4928220
- OpenAlex
- W2292284388
- Cited by
- 81
- References
- 35
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 7 · 2021: 23 · 2020: 6 · 2019: 5 · 2018: 7 · 2017: 3 · 2016: 1
- FWCI
- 10.36
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Diabetes Science and Technology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- real-time continuous glucose monitoring, type 2 diabetes, cost-effectiveness, self-monitoring of blood glucose, glycemic control, HbA1c, quality-adjusted life expectancy, disease management, prandial insulin, third-party payer perspective
- MeSH terms
- Adult, Aged, Blood Glucose, Computer Simulation, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Blood Glucose Self-Monitoring, Randomized Controlled Trials as Topic, Quality-Adjusted Life Years
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.